Real-world data from NordiNet International Outcome Study (IOS) and ANSWER Program provide new insights into the safety of growth hormone in a large cohort of children with Noonan Syndrome
Keyword(s):
Keyword(s):
Keyword(s):
2017 ◽
Vol 33
(7)
◽
pp. 564-569
◽
Keyword(s):
2020 ◽
Vol 50
◽
pp. 71-82
◽
Keyword(s):
2020 ◽